stents

Bifurcación de tronco de coronaria distal: cantidad de stents

Bifurcation Lesion in Distal Left Main Coronary Artery: One or Two Stents?

Courtesy of Dr. Carlos&nbsp;Fava. Unprotected left main coronary artery (LMCA) angioplasty has become an important trend in the last few years. &nbsp; One of the most significant unresolved questions about it is whether one stent is better than two in distal lesions, and how is their progress after treatment. &nbsp; This study included 937&nbsp;patients who<a href="https://solaci.org/en/2016/11/16/bifurcation-lesion-in-distal-left-main-coronary-artery-one-or-two-stents/" title="Read more" >...</a>

ivus vs angiografia nuevos stents farmacologicos

IVUS vs. Angiography in New-Generation Drug-Eluting Stents Preimplantation

Courtesy of Dr. Guillermo Migliaro. The latest 2011 American College of Cardiology (ACC) guideline states that “coronary intravascular ultrasonography (IVUS) may be considered for guidance of coronary stent implantation, particularly in cases of left main coronary artery stenting (Class IIB, Level of Evidence: B).” This has been long debated with no clear winners. This analysis provides new information<a href="https://solaci.org/en/2016/11/01/ivus-vs-angiography-in-new-generation-drug-eluting-stents-preimplantation/" title="Read more" >...</a>

oclusiones totales cronicas plataformas bioabsorbibles stents liberadores de droga

Chronic Total Occlusion: Bioresorbable Scaffolds or Drug Eluting Stents?

There is little evidence to support the safety and efficacy of bioresorbable scaffolds (BRS) for the treatment of chronic total occlusions (CTO). &nbsp; This multicenter registry included consecutive patients with CTO receiving BRS (Absorb; Abbott Vascular) vs. 2nd generation drug eluting stents (DES). &nbsp; Primary end point was target vessel failure at long term (composite<a href="https://solaci.org/en/2016/10/24/chronic-total-occlusion-bioresorbable-scaffolds-or-drug-eluting-stents/" title="Read more" >...</a>

Current Bare-Metal Stents: Similar to DES in the Very Long-Term

The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal infarction between current conventional stents and drug-eluting stents at over 5 years in patients with stable or unstable coronary disease. As expected, NORSTENT did find a difference in revascularization rates between both groups. &nbsp; This study presented at the<a href="https://solaci.org/en/2016/09/07/current-bare-metal-stents-similar-to-des-in-the-very-long-term/" title="Read more" >...</a>

reestenosis intrastent

Instent restenosis: Drug eluting balloons or drug eluting stents?

Original Title: Long-Term Results of Everolimus-Eluting Stents versus Drug-Eluting Balloons in Patients with Bare-Metal In-Stent Restenosis 3-Year Follow-Up of the RIBS V Clinical Trial. Reference: Alfonso F. et al.  JACC Cardiovasc Interv. 2016 Jun 27;9(12):1246-55. &nbsp; Courtesy of Dr. Agustín Vecchia. &nbsp; RIBS V 3 year follow up Stents have become the gold standard for<a href="https://solaci.org/en/2016/06/28/instent-restenosis-drug-eluting-balloons-or-drug-eluting-stents/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

LV: Everolimus Eluting Stents vs. Coronary Artery Bypass Graft

Original Title: Revascularization in Patients with Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus Eluting Stents vs Coronary Artery Bypass Graft Surgery Reference: Bangalore et al. Circulation. 2016 May 5. Epub ahead of print. &nbsp; Courtesy of Dr. Guillermo Migliaro. &nbsp; Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary<a href="https://solaci.org/en/2016/05/16/lv-everolimus-eluting-stents-vs-coronary-artery-bypass-graft/" title="Read more" >...</a>

Meta-Analysis of Bioresorbable Vascular Scaffolds vs. Everolimus Eluting Stents

&nbsp;Courtesy of Dr. Agustín Vecchia. The aim of this study was to compare the safety and efficacy of bioresorbable everolimus eluting scaffolds (BVS) vs. everolimus eluting stents (EES) in patients with ischemic heart disease. &nbsp; Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), was searched for scientific sessions, abstracts, and relevant websites for<a href="https://solaci.org/en/2016/01/19/meta-analysis-of-bioresorbable-vascular-scaffolds-vs-everolimus-eluting-stents/" title="Read more" >...</a>

Respuesta vascular tras implante de stents eluidores de biolimus A9 con polímero bioabsorbible y stents liberadores de everolimus con polímero durable. Resultados del análisis de tomografía de coherencia óptica del estudio randomizado BIOACTIVE

Daniel Chamié, Breno O. Almeida, Fábio Grandic, Evandro M. Filho, J. Ribamar Costa Jr., Ricardo Costa, Rodolfo Staicoa, Dimytri Siqueira, Fausto Feres, Luiz Fernando Tanajura,  Marinella Centemero, Áurea J. Chaves, Andrea Abizaid, Amanda G.M.R. Sousa,

Top